source
- Roche stops two Huntington's disease gene-silencing programs after disappointing trial dataRoche announced it is ending development of two gene‑silencing candidates aimed at Huntington's disease after data failed to meet expectations. The decision follows a recent readout that showed in…
- FDA rejects Hengrui-Elevar liver cancer drug combo for third time over manufacturing issuesFDA has again turned down a liver cancer drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics. This is the third rejection in roughly two years, with the agency citing per…